The Sai Parenteral IPO is currently in its final stretch. Based on the report from March 27, 2026, here is a concise breakdown of the subscription status, financial health, and expert outlook to help you evaluate the opportunity.
IPO Snapshot: Key Numbers
The issue is looking to raise ₹409 crore, split between a fresh issue for growth and an offer for sale (OFS).
- Price Band: ₹372 – ₹392 per share.
- Lot Size: 38 shares (Minimum investment of ₹14,896).
- Closing Date: Friday, March 27, 2026.
- GMP (Grey Market Premium): Currently ₹0, suggesting a flat listing (no immediate listing gains expected).
Subscription Status (Day 3)
As of the final morning, the overall response has been lukewarm, showing a divide between institutional and retail interest:
| Category | Subscription Level | Sentiment |
| NII (Non-Institutional) | 1.08x | Fully subscribed; steady interest. |
| QIB (Institutional) | 60% | Moderate; likely to see more movement toward the close. |
| Retail Investors | 7% | Very low; indicates retail caution. |
| Total | 43% | Under-subscribed as of 10:45 AM. |
Financial Performance Trends
The company has shown aggressive revenue growth over the last few years, though profit margins remain a point of observation.
- FY23: ₹97 Cr Revenue | ₹4 Cr PAT
- FY24: ₹154 Cr Revenue | ₹8 Cr PAT
- FY25: ₹495 Cr Revenue | ₹20 Cr PAT
- H1 FY26: ₹303 Cr Revenue | ₹2 Cr PAT (Note: Profitability appears lower in the first half of the current year compared to the full FY25).
Investment Rationale: Pros & Cons
The Positives (Why to “Subscribe”)
- Strategic Expansion: ₹110 crore of the proceeds are earmarked for capacity expansion and facility upgrades.
- High-Margin Focus: The company is pivoting toward injectables, which typically offer better margins than standard tablets or liquids.
- CDMO Growth: Their partnership with Noumed and a portfolio of 451 dossiers provide a solid foundation for international growth.
The Risks (Why to be Cautious)
- Premium Valuation: With a P/E multiple of 88.2x, the stock is priced significantly higher than many of its industry peers.
- Flat Listing Signal: The lack of a Grey Market Premium suggests that the market does not anticipate a “pop” on Day 1.
- Recent PAT Dip: The H1 FY26 profit (₹2 Cr) is relatively thin compared to the revenue (₹303 Cr), suggesting rising costs or compressed margins.
Verdict
Brokerages like SBI Securities suggest a “Subscribe for Long Term” approach. This IPO is likely not for “listing gain” seekers given the ₹0 GMP. Instead, it is a play on the company’s ability to scale its injectable and R&D segments over the next 2–3 years.
